What is the Revumenib?

Revumenib is , while it's Molecular Formula is C32H47FN6O4S. Used in Oncology: Revumenib is used as an anticancer agent for its potential to disrupt the growth and spread of various cancer types. It targets VEGFR, PDGFR, and FGFR signaling pathways, which are crucial for angiogenesis, tumor growth, and tumor cell survival and proliferation. Used in Preclinical Cancer Research: Revumenib is used as a potential treatment option in preclinical studies across multiple cancer models. Its efficacy in these studies highlights its potential as a therapeutic agent for a range of malignancies. Used in Drug Development: Revumenib is utilized in the development of novel cancer therapies, given its ability to target multiple receptor pathways involved in cancer progression. Its potential as a single agent or in combination with other treatments is being explored to enhance its therapeutic benefits in cancer management.

What is the CAS number for Revumenib?

The CAS number of Revumenib is 2169919-21-3.

What is Revumenib (2169919-21-3) used for?

Revumenib is a novel, orally available small molecule inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). These receptors are associated with angiogenesis, tumor growth, and tumor cell survival and proliferation. Revumenib's ability to disrupt these critical pathways makes it a promising candidate for cancer therapy.

What is the Revumenib?

Revumenib is , while it's Molecular Formula is C32H47FN6O4S. Used in Oncology: Revumenib is used as an anticancer agent for its potential to disrupt the growth and spread of various cancer types. It targets VEGFR, PDGFR, and FGFR signaling pathways, which are crucial for angiogenesis, tumor growth, and tumor cell survival and proliferation. Used in Preclinical Cancer Research: Revumenib is used as a potential treatment option in preclinical studies across multiple cancer models. Its efficacy in these studies highlights its potential as a therapeutic agent for a range of malignancies. Used in Drug Development: Revumenib is utilized in the development of novel cancer therapies, given its ability to target multiple receptor pathways involved in cancer progression. Its potential as a single agent or in combination with other treatments is being explored to enhance its therapeutic benefits in cancer management.

What is the CAS number for Revumenib?

The CAS number of Revumenib is 2169919-21-3.

What is Revumenib (2169919-21-3) used for?

Revumenib is a novel, orally available small molecule inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). These receptors are associated with angiogenesis, tumor growth, and tumor cell survival and proliferation. Revumenib's ability to disrupt these critical pathways makes it a promising candidate for cancer therapy.

Products

Product classification

small-molecule inhibitor
intermediate
Pharmaceutical intermediate
Biochemical reagent
fire retardant
chemical reagent
ionic liquid
API

Contact us

Tel：+86-0533-2185556
Fax：+86-0533-2185556
Phone：+86 15965530500
Website：http://www.shandonghangyu.com/
Email：admin@hangyubiotech.com
Address：Room 2516, Dingcheng Building, Beijing Road, Zhangdian District, Zibo City, Shandong Province

2169919-21-3

Product Name:SNDX-5613
Molecular Formula:C32H47FN6O4S
Molecular Weight:630.8

Inquiry

Product Details

Purity:99%

Manufacturer supply top purity SNDX-5613 2169919-21-3 with ISO standards

Molecular Formula:C32H47FN6O4S
Molecular Weight:630.8

Relevant Products

2-METHYL-4-(TRIFLUOROMETHYL)-1,3-THIAZOLE-5-CARBOXYLIC ACID
CAS：117724-63-7
AR 231453
CAS：733750-99-7
MRT67307
CAS：1190378-57-4
2,6-Dimethoxyisonicotinic acid
CAS：6274-82-4

Home

About us

Products

small-molecule inhibitor

intermediate

Pharmaceutical intermediate

Biochemical reagent

fire retardant

chemical reagent

ionic liquid

API

Pharmaceutical intermediates

Biological products

Polypeptides

Chemical reagents

Small molecule inhibitors

Organic electronic chemical materials

Technical Support

News

Contact Us